Could immunologic changes after mifepristone administration explain the risk of C. sordellii infection following medical abortion?
It is very unlikely that immunologic changes following use of mifepristone could make a person susceptible to only one type of bacterial infection, and there is no scientific evidence of clinical systemic immunodeficiency induced by mifepristone. If there were systemic immunological compromise, it is likely that there would be a proliferation of all types of infection, rather than the disproportionate number of rare C. sordellii infections reported thus far. In Europe, the most common regimen for mifepristone-misoprostol medical abortion uses three times the amount of mifepristone that is commonly used in the U.S. (600 mg compared to 200 mg). There have been no known reports of death due to infection or exotoxic shock in Europe. If mifepristone caused immunologic changes leading to higher susceptibility to infection, it stands to reason that more women would have died from infection in Europe than in the U.S., yet no women have died from this cause in Europe. Furthermore, mifepristone
Related Questions
- Could immunologic changes after mifepristone administration explain the risk of C. sordellii infection following medical abortion?
- Are there other risk factors that could explain the risk of C. sordellii infection following mifepristone medical abortion?
- Could the process of medical abortion explain the risk of C. sordellii infection?
